

Original Article

Expression and significance of CD4⁺CD25⁺CD127⁻ regulatory T cells in peripheral blood of patients with different phenotypes of Guillain-Barré syndrome

Hao Wang, Li Li, Yin Zhang, Shu-Chao Pan, An-Qiang Chen, Wei-Dong Qian

Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China

Received August 13, 2015; Accepted October 10, 2015; Epub October 15, 2015; Published October 30, 2015

Abstract: Objective: This study aims to investigate the changes of immune status and significance in patients with Guillain-Barré syndrome (GBS). Methods: The proportion of CD4⁺CD25⁺CD127⁻ regulatory T cells in peripheral blood before immunotherapy for 41 patients with GBS (including 29 classic type and 12 variant type) and 42 normal control patients (healthy volunteers) were evaluated by flow cytometry. And molybdenum three phenol red method was used to detect cerebrospinal fluid protein content of 28 patients with GBS (including 19 with classic type and 9 with variant type). Results: Compared with healthy control group, the CD4⁺CD25⁺CD127⁻ of GBS group had obvious difference ($P < 0.05$). Of which, the CD4⁺CD25⁺CD127⁻ regulatory T cells of the classic GBS group had no significant changes compared with the variant group ($P > 0.05$), as well as the cerebrospinal fluid protein content between classic and variant GBS groups. The decrease of the proportion of CD4⁺CD25⁺CD127⁻ regulatory T cells suggested abnormal expression of immune function in GBS patients. Conclusion: The decrease of GBS regulatory T cell number or function indicated that the immune regulatory T cells mediated imbalance of immune regulation involved in the pathogenesis of GBS.

Keywords: Regulatory T cells, Guillain-Barré syndrome, flow cytometry

Introduction

Now that the Guillain-Barré syndrome (GBS) was considered as a group of autoimmune disease. The known pathogenesis was similar to certain components due to precursor of infected pathogen and peripheral nerve myelin, the immune system cannot correctly identify the allogeneic and autologous antigen after infection, then occurred error immune response antigen to component of autologous peripheral nerve, caused peripheral nerve demyelination, secondary to axonal degeneration for severe patients [1-3]. But its principles of immunology in the pathogenesis remained unclear.

Regulatory T cells (CD4⁺CD25⁺ Tregs) were a group of T cell subsets with immune regulation function different from helper T cell (Th1 and Th2) of the human body. Such cells had immunosuppressive properties, can maintain the immune tolerance and immune homeostasis, prevented the body's autoimmune diseases [4]. The previous study confirmed that CD4⁺CD25^{high}

Treg cell number or function abnormality can cause a variety of autoimmune diseases, but the results were not entirely consistent [4-16]. In this study, three phase flow cytometry was used to detect CD4⁺CD25⁺CD127⁻ proportion in peripheral blood of 41 GBS patients, and compared with the healthy control group, in order to explore the significance of CD4⁺CD25⁺ Tregs in the pathogenesis of GBS.

Materials and methods

Subjects

41 inpatients with GBS admitted in the Department of Neurology, the First Affiliated Hospital of Bengbu Medical College during January, 2012 to November, 2014 (excluding patients with other autoimmune diseases or receiving hormone therapy immune factors) were selected. The diagnosis and classification were in line with treatment guidelines of 2010 Chinese Guillain-Barré syndrome [17]. The blood samples were collected after the patients

Table 1. Comparison of proportion of CD4⁺CD25⁺CD127⁻ Treg in CD4⁺ T cells in peripheral blood of Guillain-Barré syndrome patients and healthy controls

| Group | Typing | Cases | CD4 ⁺ CD25 ⁺ CD127 ⁻ Treg detection values (%) |
|---------|---------|-------|---|
| GBS | Classic | 29 | 3.40±1.46* |
| | Variant | 12 | 3.29±1.64* |
| | Total | 41 | 3.37±1.49* |
| Control | | 42 | 6.26±1.72 |

Note: Total GBS patient group (including the classic and variant types) was significantly lower compared with the healthy control group (* $P < 0.05$), the difference was statistically significant. Of which, compared GBS variant group with classic group, $P > 0.05$, the difference was not statistically significant.

signing informed consent after admission, and performed lumbar puncture in 2-3 weeks after the incidence. 41 cases patients who enrolled in regulatory T cells detection, including 25 males and 16 females, aged 9-76 years with mean age of 45.8 years, 19 cases sub-type was the classic type, 12 cases of variant; 28 cases were enrolled in cerebrospinal fluid detection, including 15 males and 13 females, aged 9-70 years with mean age of 42.3 years old, 19 cases were classic type, 9 cases of variant type. The control group was the healthy subjects provided by the hospital medical center, a total of 42 people including 30 males and 12 females, aged 16-58 years with a mean age 40.1 years. The study was authorized by Bengbu Medical Ethics Committee, and all participants wrote informed consent. This study was conducted in accordance with the declaration of Helsinki. This study was conducted with approval from the Ethics Committee of Bengbu Medical College. Written informed consent was obtained from all participants.

Regulatory T cell detection

Specimen collection: EDTA-K2 anticoagulant vacuum blood was used to collect 2 ml venous blood. Two streaming dedicated pipes were numbered to be Tr1 and Tr2. Added 20 μ l Anti-CD25-FITC (No. 3,295,612, US BD Biosciences), Anti-CD4-Percp (No. 3,311,518, US BD Biosciences) and the Anti-CD127-PE (No. 3,276,859, US BD Biosciences) to Tr2 pipe, respectively. 20 μ l of isotype antibody were added to Tr1 tube join as negative control at the same time. Added 100 μ l of whole blood to Tr1 and Tr2 tubes, respectively, mixed evenly, incubated in

35°C water bath in dark for 15 min. 2.0 mL of Lysing hemolytic solution (NH_4Cl) were added to the two tubes, and bathed in 35°C water in dark for 10 min. Centrifuged at 500 rev/min for 5 min, the supernatant was discarded. Saline (PBS) cells were washed twice with 1500 rpm/min centrifugal 5 min, the supernatant was discarded. 0.5 ml of 1% paraformaldehyde (PFA) was added to each group to fix. Flow cytometry (FACS Calibur, purchased from BD Biosciences) was used to test.

According to the lateral light scattering (FSC) and longitudinal optical (SSC) scattering scatterplot, set the lymphocyte gate. 10000 lymphocytes of each specimen was collected, the results were analyzed by Cell Quest software.

Determination of protein content

Specimen collection: a dry tube (Z) vacuum, 2 ml of cerebrospinal fluid specimens (not hemolysis) was centrifuged at 500 rev/min for 5 min, and 5 μ l of the supernatant were collected and numbered to be T1. 5 μ l of standard product (excluding serum albumin solution) (Code: 8050-717, China Ruiyuan biotechnology) was collected and number to be T2, then added 300 μ l of the reagent (the main component was pyrogallol red buffer), mixed and incubated at 37°C for 600 s, measured the absorbance A after water blank to be zero, according to CSF protein (mg/dl) = standard sample concentration \times A/standard A, the data were statistically analyzed.

Statistical analysis

All data were expressed as mean \pm standard deviation ($\bar{x} \pm s$). SPSS17.0 software package was used for statistical analysis. The difference between the t test was compared. $P < 0.05$ was considered to be statistically significant.

Results

Comparisons between GBS and healthy control groups: GBS total patient group (including the classic type and variant) had significantly reduced compared with the healthy control group, the difference was statistically significant ($P < 0.05$; **Table 1**; **Figure 1A, 1B**).

Comparisons between classic GBS and variant groups: compared with the GBS variant group, the ratio of CD4⁺CD25⁺CD127⁻ regulatory T cells in the classic group had no significant differ-




Figure 1. Comparisons of flow cytometry charts for CD4⁺CD25⁺CD127⁻ regulatory T cells in peripheral blood of healthy, classic and variant GBS type patients. A: Flow cytometry chart for CD4⁺CD25⁺CD127⁻ regulatory T cells in peripheral blood of healthy patients, and gated the CD4⁺ T lymphocyte. B: Flow cytometry charts for CD4⁺CD25⁺CD127⁻ regulatory T cells in peripheral blood of classic GBS type patients. C: Flow cytometry charts for CD4⁺CD25⁺CD127⁻ regulatory T cells in peripheral blood of variant GBS type patients.

Table 2. Comparison of cerebrospinal fluid protein content between the patients with classic and variant Guillain-Barré syndrome (mg/dl)

| Typing | Cases | Cerebrospinal fluid protein content |
|---------|-------|-------------------------------------|
| Classic | 19 | 1.07±0.41 |
| Variant | 9 | 0.99±0.28 |

Note: Cerebrospinal fluid protein content changes of patients with classic and variant GBS had no significant differences ($P>0.05$), the differences were not statistically significant.

ence ($*P>0.05$), the difference was not statistically significant, as well as the cerebrospinal fluid protein content ($**P>0.05$; **Table 1**; **Figure 1B, 1C**).

Discussion

Sakaguchi et al. [18] formally proposed by animal experiments in 1995 that CD4⁺CD25⁺ T

cells had function of active immune suppression, then such cells were widely paid attention to by immunologists. As different from the immune suppressor T cells in the traditional theory, these cells were named for life “CD4⁺CD25⁺ regulatory T cells” (CD4⁺CD25⁺ Tregs). Previous studies for classical Scurfy mouse model [19, 20] suggested that Foxp3 and its coding products were sensitive and specific markers of regulatory T cells, which played an important role in the regulation of T cell development and function. But Shevach research team [21, 22] found that different from rodents, Foxp3 expression in CD4⁺CD25⁺ Treg in human had differences; and it was thought that Foxp3 was not regulatory T cell-specific markers. Previous literature confirmed that 5%-10% of CD4⁺CD25⁺ Treg cells existed in peripheral blood of human, but CD25 expression in peripheral blood of human and mouse was significantly different. The number of CD25 on the CD4⁺ T cell surface was uniform, there was a

clear demarcation between CD4⁺CD25⁺ and CD4⁺CD25⁻ T cells, which was a single cell population independent of each other. While the CD25 expression on human CD4⁺ T cell surface can be divided into weak, medium, strong three levels according to the number or fluorescence intensity. The previous studies suggested that CD25 strongly positive CD4⁺ T cells (CD4⁺CD25^{high}) can specifically express CD4⁺CD25⁺ Treg cells [23]. But function molecules (Foxp3) of regulatory T-cell located in the nucleus, the detection of which needed rupture markers, test procedures were cumbersome. Liu et al. [24] found in 2006 that the membrane surface molecules IL-7 receptor CD127 expression was negatively correlated with FoxP3, this molecule inhibited CD4⁺ Treg cell function. Through detecting human Treg cell subpopulations CD127 molecules in peripheral blood of patients with type 1 diabetes, the molecule was proved to be used as Tregs cell surface markers. Study of Yu et al. [25] confirmed that low expression of CD127 molecule was an inherent characteristic of Tregs cells, CD4⁺CD25⁺CD127⁻ markers can accurately assess the number of human Treg cells and subsequent function of regulatory T cells in vitro. The studies of Klein et al. [26] believed that as CD4⁺CD25⁺ Treg cell surface markers in human peripheral blood, two indicators (CD4⁺CD25⁺CD127⁻ T cells and CD4⁺CD25⁺FoxP3) had good correlation, and CD4⁺CD25⁺CD127⁻ mark method was thought to be more ideal indicators of human CD4 than CD4⁺CD25⁺FoxP3 mark method. Saison et al. [5] studied the human autoimmune disease systemic lupus erythematosus and demonstrated that CD4⁺CD25⁺CD127⁻ T cells was positive correlated with CD4⁺CD25⁺FoxP3. Therefore, this study used CD4⁺CD25⁺CD127⁻ as a detection indicator for CD4⁺CD25⁺ Treg. The proportional changes of CD4⁺CD25⁺CD127⁻ in patients with GBS were detected, and CD4⁺CD25⁺CD127⁻ in GBS pathogenesis were analyzed to explore the clinical application significance.

Regulatory T cells (Tregs) mainly had two characteristics including immune incompetence and immunosuppressive, the mechanism of action was negative role in immune regulation by dependent direct contact inhibition and independent secretion of cytokine inhibition. Its molecular basis of the immune inhibitory mainly ① through suppressing effector T cells by cytotoxic T lymphocyte-associated antigen 4

(CTLA-4) dependent direct cell contact manner; ② inhibiting CD4⁺ T cell activation and proliferation by secreting inhibitory cytokines IL-10 or TGF-β, or directly inhibiting CD8⁺ effector T cells and their precursor cells; ③ inhibiting CD4⁺ T cell activation and proliferation by increasing the metabolism of tryptophan (Trp) via acting on antigen-presenting cells (APC) mode; ④ CD4⁺CD25⁺ Treg inducing local formation of target cells into micro-environment immunosuppressive environment, so that part of CD4⁺CD25⁺ T cells can be induced by CD4⁺CD25⁺ Treg and secreted IL-10 or TGF-β to exert immunosuppressive effects [6]; ⑤ CD4⁺CD25⁺ Treg also interfering with the proliferation of CD8⁺ T effector T cells, inhibiting the secretion of cytokines and the ability of cytotoxicity through this local microenvironment [4, 15, 16].

GBS was a CD4⁺ T cell-dependent autoimmune disease, CD4⁺ T cell activation was the key to the disease [7]. The study found that the decrease of CD4⁺CD25⁺ Treg before immunotherapy in GBS group was significantly different from the normal control group, but there was no significant difference (**Table 1**). The level changes of cerebrospinal fluid protein content of GBS classic group had no significant difference compared with the variant group (**Table 2**), suggesting that CD4⁺CD25⁺ Treg played an important role in the pathogenesis, development process of GBS patients. The cerebrospinal fluid protein content levels before immunotherapy in patients with GBS had no significant correlation with the types of disease, which was consistent with the existing literature. The effective human serum immunoglobulin therapy prompted the process of GBS immune involved in both humoral and cellular immunity [8, 10]. The number decrease or function decline of CD4⁺CD25⁺ Treg in peripheral blood of GBS may be due to: 1) decreased production: decreased production or dysfunction of Treg cells caused by thymic dysfunction in patients with GBS; 2) the abnormal distribution: Treg cells migrated to the nerve root with lesions and locally gathered around small blood vessels, then resulted in a reduction in the number of peripheral blood; 3) abnormal differentiation: a significant increase in inflammatory cytokines such as interleukin-6 (IL-6) as a result of inhibition of the differentiation of Treg cells. CD4⁺CD25⁺ Treg played a negative role in immune regulation through regulating effector T cells, that is, CD4⁺CD25⁺ Treg played roles of direct contact

inhibition and secreting of inhibition cytokines IL-10 and TGF- β by CTLA-4 and glucocorticoid-induced tumor necrosis by cytotoxic factor receptor (GITR) to suppress autoreactive T cell proliferation and activation and played a negative role in immunoregulatory. Thus, the decline number of or function for Treg cells with immune suppression perhaps resulted in immune regulation dysfunction in GBS patients, inhibited effector T cell function decline and triggered an autoimmune response, caused immune damage, finally lead to the occurrence of the disease [4, 27].

CD4⁺CD25⁺ Treg cell was an important factor in maintaining immune homeostasis itself. The treatment of autoimmune diseases by inducing autologous exogenous CD4⁺ T cells for the CD4⁺CD25⁺ Treg cells in vitro and transferred into the patients has been confirmed in animal experiments and some autoimmune diseases [11-14, 28]. Clinical widely use of CD4⁺CD25⁺ Treg had an important role in autoimmunity, transplantation immunology, infectious immunity, tumor immunology and reproductive immunology. However, the mechanisms and activation pathways of CD4⁺CD25⁺ Treg in disease was not entirely clear, which required the joint efforts of colleagues, to find a new theory for the clinical application of CD4⁺CD25⁺ Treg in autoimmune diseases.

Acknowledgements

This study was supported by Natural Science Foundation of Anhui Higher Education Institutions and Graduate Innovation Program of Bengbu Medical College (No. Byycx1314).

Disclosure of conflict of interest

None.

Address correspondence to: Wei-Dong Qian, Department of Neurology, The First Affiliated Hospital of Bengbu Medical College, No. 287 Chang Huai Road, Bengbu 233004, China. Tel: +86 135055-23288; E-mail: weidongqiandoc@sina.com

References

- [1] Nyati KK and Prasad KN. Role of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barré syndrome. *Mediators Inflamm* 2014; 2014: 758639.
- [2] Nyati KK, Prasad KN, Kharwar NK, Soni P, Husain N, Agrawal V and Jain AK. Immunopathol-

- ogy and Th1/Th2 immune response of *Campylobacter jejuni*-induced paralysis resembling Guillain-Barré syndrome in chicken. *Med Microbiol Immunol* 2012; 201: 177-187.
- [3] Gächter C, Petersen JA, Schwarz U, Pangalu A and Tarnutzer AA. Teaching NeurolImages: Variant of Guillain-Barré syndrome with spinal cord involvement. *Neurology* 2015; 84: e30.
- [4] Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H and Khazaie K. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. *Proc Natl Acad Sci U S A* 2005; 102: 419-424.
- [5] Saison J, Demaret J, Venet F, Chidiac C, Malcus C, Poitevin-Later F, Tardy JC, Ferry T and Monneret G. CD4⁺CD25⁺CD127⁻ assessment as a surrogate phenotype for FOXP3⁺ regulatory T cells in HIV-1 infected viremic and aviremic subjects. *Cytometry B Clin Cytom* 2013; 84: 50-54.
- [6] Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J and Enk AH. Infectious tolerance: human CD25⁺ regulatory T cells convey suppressor activity to conventional CD4⁺ T helper cells. *J Exp Med* 2002; 196: 255-260.
- [7] Yoshii F and Shinohara Y. Lymphocyte subset proportions in Guillain-Barré syndrome patients treated with plasmapheresis. *Eur Neurol* 2000; 44: 162-167.
- [8] Bhargava A, Banakar BF, Pujar GS and Khichar S. A study of Guillain-Barré syndrome with reference to cranial neuropathy and its prognostic implication. *Neurosci Rural Pract* 2014; 5: S43-47.
- [9] Paasela M, Kolho KL, Vaarala O and Honkanen J. Lactose inhibits regulatory T-cell-mediated suppression of effector T-cell interferon- γ and IL-17 production. *Br J Nutr* 2014; 112: 1819-1825.
- [10] Lainez-Andres JM, Gascon-Gimenez F, Coret-Ferrer F, Casanova-Estruch B and Santonja JM. Therapeutic plasma exchange: applications in neurology. *Rev Neurol* 2015; 60: 120-131.
- [11] Hagmann S, Gotterbarm T, Müller T, Baesig AM, Gantz S, Dreher T, Kämmerer PW, Frank S, Zeifang F and Moradi B. The influence of bone marrow- and synovium-derived mesenchymal stromal cells from osteoarthritis patients on regulatory T cells in co-culture. *Clin Exp Immunol* 2013; 173: 454-462.
- [12] Kobayashi T, Nakatsuka K, Shimizu M, Tamura H, Shinya E, Atsukawa M, Harimoto H, Takahashi H and Sakamoto C. Ribavirin modulates the conversion of human CD4(+) CD25(-) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. *Immunology* 2012; 137: 259-270.
- [13] Pihl M, Akerman L, Axelsson S, Chéramy M, Hjorth M, Mallone R, Ludvigsson J and Casas

- R. Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes. *Clin Exp Immunol* 2013; 172: 394-402.
- [14] Fan H, Yang J, Hao J, Ren Y, Chen L, Li G, Xie R, Yang Y, Gao F and Liu M. Comparative study of regulatory T cells expanded ex vivo from cord blood and adult peripheral blood. *Immunology* 2012; 136: 218-230.
- [15] Di Caro V, D'Anneo A, Phillips B, Engman C, Harnaha J, Lakomy R, Styche A, Trucco M and Giannoukakis N. Interleukin-7 matures suppressive CD127(+) forkhead box P3 (FoxP3)(+) T cells into CD127(-) CD25(high) FoxP3(+) regulatory T cells. *Clin Exp Immunol* 2011; 165: 60-76.
- [16] Engela AU, Hoogduijn MJ, Boer K, Litjens NH, Betjes MG, Weimar W and Baan CC. Human adipose-tissue derived mesenchymal stem cells induce functional de-novo regulatory T cells with methylated FOXP3 gene DNA. *Clin Exp Immunol* 2013; 173: 343-354.
- [17] Wakerley BR, Uncini A, Yuki N, GBS Classification Group and GBS Classification Group: Guillain-Barré and Miller Fisher syndromes—new diagnostic classification. *Nat Rev Neurol* 2014; 10: 537-544.
- [18] Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol* 1995; 155: 1151-1164.
- [19] Kuhn A, Beissert S and Krammer PH. CD4⁺CD25⁺ regulatory T cells in human lupus erythematosus. *Arch Dermatol Res* 2009; 301: 71-81.
- [20] Khattri R, Cox T, Yasayko SA and Ramsdell F. An essential role for Scurfin in CD4⁺CD25⁺ T regulatory cells. *Nat Immunol* 2003; 4: 337-342.
- [21] Shevach EM. CD4⁺CD25⁺ suppressor T cells: more questions than answers. *Nat Rev Immunol* 2002; 2: 389-400.
- [22] Williams LM and Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. *Nat Immunol* 2007; 8: 277-284.
- [23] Baecher-Allan C, Viglietta V and Hafler DA. Human CD4⁺CD25⁺ regulatory T cells. *Semin Immunol* 2004; 16: 89-98.
- [24] Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4⁺ T reg cells. *J Exp Med* 2006; 203: 1701-1711.
- [25] Yu N, Li X, Song W, Li D, Yu D, Zeng X, Li M, Leng X and Li X. CD4⁺CD25⁺CD127^{low/-} T cells: a more specific Treg population in human peripheral blood. *Inflammation* 2012; 35: 1773-1780.
- [26] Klein S, Kretz CC, Krammer PH and Kuhn A. CD127(low/-) and FoxP3(+) expression levels characterize different regulatory T-cell populations in human peripheral blood. *J Invest Dermatol* 2010; 130: 492-499.
- [27] Lange C, Scholl M, Melms A and Bischof F. CD62L(high) Treg cells with superior immunosuppressive properties accumulate within the CNS during remissions of EAE. *Brain Behav Immun* 2011; 25: 120-126.
- [28] Horwitz DA, Zheng SG, Gray JD, Wang JH, Ohtsuka K and Yamagiwa S. Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. *Semin Immunol* 2004; 6: 135-143.